Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 271 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjVTWM2OD1yLkC2NUDPxE1? MWfTRW5ITVJ?
ALL-PO MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3TcpZTUUN3ME2wMlA3OzV3IN88US=> M{Lj[3NCVkeHUh?=
697 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i2NWlEPTB;MD6wPVk4PiEQvF2= MUDTRW5ITVJ?
NCI-H748 M2\IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRdmlEPTB;MD6xNFM{PCEQvF2= NGTVRnRUSU6JRWK=
NKM-1 NWrJfXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWx[JRnUUN3ME2wMlExQTF{IN88US=> NVHDO2RoW0GQR1XS
ES1 NYDjeYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn3TWM2OD1yLkGxNlU2KM7:TR?= NUT1ZmN{W0GQR1XS
NCI-H1963 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrlbYJKSzVyPUCuNVE2PzlizszN MU\TRW5ITVJ?
NCI-H1417 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPWbW9UUUN3ME2wMlEzQTd2IN88US=> NUHSTotVW0GQR1XS
NEC8 NIPQbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUO1Nlch|ryP MnvJV2FPT0WU
CRO-AP2 NYS0e2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZN2lEPTB;MD6xOlg5QSEQvF2= NH32cWlUSU6JRWK=
A3-KAW NYf0U5V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;VTWM2OD1yLkG3OlI4KM7:TR?= NGHOWXBUSU6JRWK=
SF539 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKUGhKSzVyPUCuNVk2QTNizszN NGD6bIpUSU6JRWK=
NOS-1 M4\iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4R|NEUUN3ME2wMlE6PjF7IN88US=> NWXB[lRLW0GQR1XS
NTERA-S-cl-D1 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDBTWM2OD1yLkKwNVE{KM7:TR?= NWPv[2tXW0GQR1XS
COR-L88 M4PSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzSTWM2OD1yLkKyPVU6KM7:TR?= MX7TRW5ITVJ?
EM-2 NGXsXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7XTWM2OD1yLkK0NFc6KM7:TR?= MYnTRW5ITVJ?
KARPAS-45 NILQXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMke4N|Mh|ryP MnP0V2FPT0WU
DSH1 NHK4PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LZcmlEPTB;MD6yPFcxQCEQvF2= NV3zb4NXW0GQR1XS
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTySlBkUUN3ME2wMlMxOjV4IN88US=> MVTTRW5ITVJ?
ATN-1 NXLXZYRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjrbHFFUUN3ME2wMlMxPTd4IN88US=> NEHRd4xUSU6JRWK=
HEL NUPTOIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom1TWM2OD1yLkOxN|Q5KM7:TR?= NHnhRWZUSU6JRWK=
NB12 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqzTWM2OD1yLkOxO|U3KM7:TR?= NVvFfYVTW0GQR1XS
LU-139 M3L0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfSTWM2OD1yLkOzOVEh|ryP NHj2TodUSU6JRWK=
J-RT3-T3-5 M1y2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwM{O3NVYh|ryP M2PpcHNCVkeHUh?=
MOLT-13 NWm0[Hl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{O4NUDPxE1? M2nwWHNCVkeHUh?=
SR NFjJNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnGTWM2OD1yLkO0NlYyKM7:TR?= NGHuUW5USU6JRWK=
CMK MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnPfVk1UUN3ME2wMlM2PzJ5IN88US=> NXfjVFF1W0GQR1XS
ES8 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknYTWM2OD1yLkO2NFIzKM7:TR?= NXjpclAyW0GQR1XS
LB647-SCLC NEPuUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCw[VZ2UUN3ME2wMlM3PzNizszN MljzV2FPT0WU
TE-8 NF:xNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHzelRKSzVyPUCuN|Y6OzVizszN NX\DWWg5W0GQR1XS
BV-173 M3j6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLPNVJKSzVyPUCuN|cyOjFizszN NV20VIR5W0GQR1XS
DEL NYjUS21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CwfmlEPTB;MD6zO|Q5PyEQvF2= NHLvb5RUSU6JRWK=
ARH-77 M{TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwM{ixPVMh|ryP NFjwT|dUSU6JRWK=
NCCIT NH\sPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwM{i2OFkh|ryP M1[zenNCVkeHUh?=
RPMI-8402 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX3TWM2OD1yLkO4O|AyKM7:TR?= MWrTRW5ITVJ?
MONO-MAC-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\IbmdKSzVyPUCuN|g4PzZizszN NGnubopUSU6JRWK=
SK-MM-2 NX3OU2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHrTWM2OD1yLkO5PFY5KM7:TR?= MYXTRW5ITVJ?
CHP-126 NYfKSldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMbHJKSzVyPUCuOFAzOzFizszN NUS3RYg6W0GQR1XS
A101D NVLvdZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HQXGlEPTB;MD60NFMh|ryP NGDpUopUSU6JRWK=
SCH NWC0cXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH20WXdKSzVyPUCuOFA{PDJizszN NX;NdXFUW0GQR1XS
NMC-G1 M{XNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNECzOlch|ryP MmP1V2FPT0WU
NCI-H209 NUDF[IIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWTHhKSzVyPUCuOFA3OTNizszN MmDOV2FPT0WU
MOLT-16 NEX3S3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DISGlEPTB;MD60NVAyPyEQvF2= MoDKV2FPT0WU
RPMI-6666 NFjZ[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfsOZFKSzVyPUCuOFEyOiEQvF2= MljsV2FPT0WU
OPM-2 NWSx[oZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe1RWVVUUN3ME2wMlQyPTF|IN88US=> NXvPOGpUW0GQR1XS
MRK-nu-1 M17pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwNEOxOVMh|ryP NF:2b4tUSU6JRWK=
BC-1 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiwb2dvUUN3ME2wMlQ{PDB|IN88US=> NYWwdXRQW0GQR1XS
MHH-NB-11 NXjINFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LEXGlEPTB;MD60N|Q2OyEQvF2= NIH2foZUSU6JRWK=
Ramos-2G6-4C10 NV3zRmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETuOHhKSzVyPUCuOFM5QTdizszN NXzBXoZsW0GQR1XS
LS-513 NHS5epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNES1NFEh|ryP M1PmZXNCVkeHUh?=
K5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkUGlEPTB;MD60O|AzPSEQvF2= MonpV2FPT0WU
HOP-62 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD1yLkS4N|U5KM7:TR?= NF;uXI9USU6JRWK=
NCI-H187 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oUnNSUUN3ME2wMlQ6OjJ5IN88US=> NYTkbXNtW0GQR1XS
BE-13 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnMc4ZKSzVyPUCuOFk3PjFizszN M3HSSXNCVkeHUh?=
HC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rPS2lEPTB;MD61NFQ4OyEQvF2= MX3TRW5ITVJ?
ACN NWq5fHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwNUGwNlgh|ryP MWLTRW5ITVJ?
HCC1599 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwNUG1O{DPxE1? NF;SOnBUSU6JRWK=
MV-4-11 NHK4dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qwR2lEPTB;MD61N|A1OSEQvF2= MXPTRW5ITVJ?
LC-2-ad MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwNUO2OlMh|ryP MY\TRW5ITVJ?
HL-60 M4fUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmWIVKSzVyPUCuOVQzPjFizszN NULZ[lRSW0GQR1XS
NB17 NGnQdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uO2lEPTB;MD61OFM5KM7:TR?= NHXuWWNUSU6JRWK=
TE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfz[ZNCUUN3ME2wMlU2OzB4IN88US=> M3HOU3NCVkeHUh?=
NCI-H524 NH7GdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17iVGlEPTB;MD61OVQxOSEQvF2= NFHvU|lUSU6JRWK=
MZ7-mel MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxW2RKSzVyPUCuOVYyODVizszN NHTLR4hUSU6JRWK=
L-363 NFjoPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwRnhKSzVyPUCuOVY3PTdizszN M4rOW3NCVkeHUh?=
BL-41 NYe4ZoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70WlRKSzVyPUCuOVY5QDlizszN MmnvV2FPT0WU
LU-134-A M{\1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF31U4FKSzVyPUCuOVcxPzNizszN MUXTRW5ITVJ?
SIG-M5 NFzTUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;UbYVKSzVyPUCuOVc5PDhizszN MoKyV2FPT0WU
ONS-76 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPCfVJLUUN3ME2wMlU5OjR{IN88US=> NVLleGhDW0GQR1XS
KARPAS-299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwNUi1NFQh|ryP Mn\YV2FPT0WU
DU-4475 NFfQeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiSlBKSzVyPUCuOVg4ODNizszN NX\DSYs1W0GQR1XS
NB69 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNUm4NlUh|ryP NWC5U2lmW0GQR1XS
MHH-PREB-1 M2\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvjUIxKSzVyPUCuOlA4OTlizszN MXHTRW5ITVJ?
LU-165 NU\jeYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwNkG4NVIh|ryP NF\GO|NUSU6JRWK=
LOUCY NXnuZmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwNkOzOlQh|ryP MmfCV2FPT0WU
NCI-H526 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;qZVUyUUN3ME2wMlY{PTRzIN88US=> NGe2UYhUSU6JRWK=
KE-37 M{DTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToT2VKSzVyPUCuOlQzPzZizszN NWH6blR3W0GQR1XS
NALM-6 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNkS4OkDPxE1? NWPiW|RmW0GQR1XS
CW-2 NX2wemlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HGbGlEPTB;MD62OVc6PCEQvF2= M{fZeHNCVkeHUh?=
SU-DHL-1 NETsZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNkW5OFch|ryP Ml;sV2FPT0WU
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1yLk[2PFE4KM7:TR?= NWHXUm9IW0GQR1XS
QIMR-WIL NGnudpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPWT5E5UUN3ME2wMlY5OzR|IN88US=> NVfWUJJEW0GQR1XS
ECC12 NH\DTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX2eYRKSzVyPUCuO|AxQDZizszN MmfHV2FPT0WU
KALS-1 NVv1e2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr3XldKSzVyPUCuO|A1QTJizszN MlfCV2FPT0WU
COR-L279 NXLJemVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTjUYNLUUN3ME2wMlcxQTl4IN88US=> MlK3V2FPT0WU
NB14 Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1yLkeyOlE4KM7:TR?= NGXENJhUSU6JRWK=
CCRF-CEM NUTJbXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwN{S2OlEh|ryP MXXTRW5ITVJ?
SW954 NWPkbHpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjkWotGUUN3ME2wMlc2QTl7IN88US=> MXfTRW5ITVJ?
IST-SL1 NGXINZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Kco1DUUN3ME2wMlc4OzR6IN88US=> MXHTRW5ITVJ?
LAMA-84 NYfR[2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m4V2lEPTB;MD63O|U3PyEQvF2= MoXJV2FPT0WU
Daudi MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PEUmlEPTB;MD63O|Y5OSEQvF2= NFPSPWtUSU6JRWK=
BC-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHhOGlKSzVyPUCuO|g{ODhizszN MYLTRW5ITVJ?
HCC2998 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwN{izOkDPxE1? NEPub5JUSU6JRWK=
NCI-H69 M1fPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXZTWM2OD1yLkiwNVQ4KM7:TR?= NV7mdIp7W0GQR1XS
CPC-N M1ezXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfvTWM2OD1yLkiwOVI1KM7:TR?= M{LVUHNCVkeHUh?=
NOMO-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHLeFFKSzVyPUCuPFExQDRizszN Ml;xV2FPT0WU
CESS NX7uR4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWzTWM2OD1yLkixNVk4KM7:TR?= MWPTRW5ITVJ?
LC4-1 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwOESwNFch|ryP NFv3dXJUSU6JRWK=
BL-70 M3KyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1RZJKSzVyPUCuPFU4ODJizszN MoPvV2FPT0WU
ES4 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuSXpYUUN3ME2wMlg2QDZ6IN88US=> MnXRV2FPT0WU
HCE-T NGnxbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfPTWM2OD1yLki3NVcyKM7:TR?= Mn3xV2FPT0WU
JAR NEPRUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1yLki3PFI4KM7:TR?= M{jHZ3NCVkeHUh?=
ST486 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nHfGlEPTB;MD64O|kyPyEQvF2= NGXu[WVUSU6JRWK=
KS-1 NH;FfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH2TWM2OD1yLki4NFk3KM7:TR?= NEX6Zo9USU6JRWK=
GDM-1 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG4NXRZUUN3ME2wMlg5Pjh5IN88US=> MmDEV2FPT0WU
EHEB NIDEVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXlTWhKSzVyPUCuPVI2QDVizszN NI[2Um1USU6JRWK=
LB2518-MEL MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwOUOyPFQh|ryP MYXTRW5ITVJ?
GOTO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTtTWM2OD1yLkm1NFc3KM7:TR?= NH62SGlUSU6JRWK=
LXF-289 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDyTWM2OD1yLkm1PVAyKM7:TR?= MkDPV2FPT0WU
ES6 M3fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwOU[0N|ch|ryP M1e0OnNCVkeHUh?=
OS-RC-2 NHe4OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xNXpKSzVyPUCuPVY5OyEQvF2= MlyxV2FPT0WU
DMS-153 NUGyZYVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfYXZlWUUN3ME2wMlk4PDZ7IN88US=> NXT4cVZIW0GQR1XS
SK-PN-DW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwOUe4N|Eh|ryP M3fQTHNCVkeHUh?=
HH MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL4fI9KSzVyPUCuPVg6PTlizszN MWfTRW5ITVJ?
SH-4 NF;HSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonBTWM2OD1zLkCyOFEh|ryP NXrzPYVmW0GQR1XS
MOLT-4 NXfJWnBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXoVZNMUUN3ME2xMlA{PDV2IN88US=> MVTTRW5ITVJ?
TGW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2ySlVKSzVyPUGuNFc3PzVizszN NEL0PJJUSU6JRWK=
L-540 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH30fGVKSzVyPUGuNVA3ODRizszN NVyzdW1ZW0GQR1XS
PF-382 NWfVeZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPldlNKSzVyPUGuNVE2OTNizszN NXPvZ3pCW0GQR1XS
LC-1F MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDeYFYUUN3ME2xMlEzODB5IN88US=> Ml\uV2FPT0WU
OVCAR-4 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP3OZJKSzVyPUGuNVMyPjVizszN NWfrbYlvW0GQR1XS
A4-Fuk Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Cx[GlEPTB;MT6xOVM3PCEQvF2= MXrTRW5ITVJ?
HCC2218 NWjtXoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwMU[2OFEh|ryP M{nTUXNCVkeHUh?=
HAL-01 NVnHR4M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{izfWlEPTB;MT6xOlk1OyEQvF2= M1;Q[nNCVkeHUh?=
IST-MEL1 NVPzR4VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPiTWM2OD1zLkG3OlU6KM7:TR?= NGLNVpZUSU6JRWK=
NCI-H719 NXrNWGtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwMUe4PVgh|ryP NV:xd|EyW0GQR1XS
EVSA-T NWPUNmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1zLkG4NVE1KM7:TR?= MXLTRW5ITVJ?
SK-NEP-1 NX7yN5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3[4hKSzVyPUGuNlAzPjZizszN MofhV2FPT0WU
OCUB-M MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwMkG0PFkh|ryP MkDnV2FPT0WU
MEG-01 NYrsWXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkixTWM2OD1zLkKyNVE5KM7:TR?= NHWwdppUSU6JRWK=
no-10 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwMkOxNVIh|ryP NXrXXW9YW0GQR1XS
MHH-CALL-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHBXWtKSzVyPUGuNlQ4OjFizszN NY\JdoNTW0GQR1XS
SK-N-DZ MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwMkS3O|Yh|ryP NEXxc4dUSU6JRWK=
SCLC-21H MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW3fYZ3UUN3ME2xMlI3PDd6IN88US=> NFXtephUSU6JRWK=
CTV-1 NYDvPXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDjZodKSzVyPUGuNlc1OjVizszN M1jyXnNCVkeHUh?=
NB1 NV7Y[JpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXSVXNoUUN3ME2xMlI4PzN{IN88US=> Mk\EV2FPT0WU
NCI-H64 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j4bmlEPTB;MT6yPFQ3OiEQvF2= MVPTRW5ITVJ?
MDA-MB-134-VI Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS2TWM2OD1zLkK4OVc4KM7:TR?= NHPUd2NUSU6JRWK=
LB2241-RCC MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\hNoI{UUN3ME2xMlI5PjZ|IN88US=> NVS4dHQ6W0GQR1XS
8-MG-BA NH;zXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD1zLkK4PFY3KM7:TR?= NXy4N5R6W0GQR1XS
LP-1 NUDjV25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DCUmlEPTB;MT6yPVk1PyEQvF2= NVPIe5JMW0GQR1XS
LS-411N NH3vbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwM{C5PVgh|ryP NH7xV5pUSU6JRWK=
CAL-148 NIXJWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32wdGlEPTB;MT6zNlU1OiEQvF2= NYDtSpVLW0GQR1XS
NCI-H2171 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwM{S1NFIh|ryP M4m0XnNCVkeHUh?=
JiyoyeP-2003 NF:2RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwM{WzPUDPxE1? MUDTRW5ITVJ?
NCI-H2107 NHizc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwM{W4PFMh|ryP MX7TRW5ITVJ?
BB30-HNC NH7SU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HFRmlEPTB;MT6zPFk4QCEQvF2= NXiyZoRFW0GQR1XS
K-562 NYPF[INHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnlTWM2OD1zLkO5NlE6KM7:TR?= NWL3R2hQW0GQR1XS
PSN1 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u4PWlEPTB;MT60NlI5PyEQvF2= MmLYV2FPT0WU
HCC2157 NFrye2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz6NXVDUUN3ME2xMlQzPjlzIN88US=> NUPPbWwxW0GQR1XS
SBC-1 NFjsVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HhemlEPTB;MT60Nlc1OSEQvF2= MWDTRW5ITVJ?
MC116 M2TyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwNEO2NVUh|ryP M4TDWHNCVkeHUh?=
KARPAS-422 NUS0dVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn2e3pxUUN3ME2xMlQ2OzV6IN88US=> NVH5VJMzW0GQR1XS
LB996-RCC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwNEexNFMh|ryP MWXTRW5ITVJ?
MSTO-211H NEPGSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYUmFwUUN3ME2xMlQ4QTh5IN88US=> MkT5V2FPT0WU
BT-474 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTYNI1KSzVyPUGuOVE4PjRizszN M2q0XHNCVkeHUh?=
A388 NEi5VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7EXZBKSzVyPUGuOVE6PDVizszN NGTESJlUSU6JRWK=
SJSA-1 NWLuWJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxcHpKSzVyPUGuOVIzPiEQvF2= MkXTV2FPT0WU
COLO-829 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPVTWM2OD1zLkWzOVY1KM7:TR?= NVfWc5pzW0GQR1XS
KM-H2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTldFNrUUN3ME2xMlU3PjdizszN NH\iWmNUSU6JRWK=
GR-ST NILj[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwNU[4NkDPxE1? M{W5WHNCVkeHUh?=
RPMI-8866 NFzEfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwNkCxOFQh|ryP NUnHTJdRW0GQR1XS
KG-1 NILkTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XnZ2lEPTB;MT62NVkxOSEQvF2= MlTtV2FPT0WU
NCI-H82 NFy4U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPFTWM2OD1zLk[zOFA3KM7:TR?= NX7oSGJ7W0GQR1XS
LB1047-RCC MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzITWM2OD1zLk[zOFU6KM7:TR?= NU\CRnZbW0GQR1XS
KM12 NWTHXotCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6yTWM2OD1zLk[0O{DPxE1? NILDdYJUSU6JRWK=
NB5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PEZmlEPTB;MT62OVY4PyEQvF2= M13HUXNCVkeHUh?=
HDLM-2 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHHUmNKSzVyPUGuOlgzQDFizszN M1zVSXNCVkeHUh?=
KU812 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXxTWM2OD1zLk[5OlA2KM7:TR?= MVHTRW5ITVJ?
DB M1PsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\O[W55UUN3ME2xMlcxOzV|IN88US=> NGrUSolUSU6JRWK=
HD-MY-Z MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrBTWM2OD1zLke1NlM1KM7:TR?= M2\ZSXNCVkeHUh?=
KURAMOCHI Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwN{eyNFch|ryP MVPTRW5ITVJ?
ETK-1 NX21TYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf2TWM2OD1zLke4PFc6KM7:TR?= M{nuVnNCVkeHUh?=
SK-UT-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Rb5ZKSzVyPUGuO|k{QDhizszN NHTLPJpUSU6JRWK=
HUTU-80 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;zVZJKSzVyPUGuO|k2ODhizszN NWToco9LW0GQR1XS
ES7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTQfZRQUUN3ME2xMlgxOzB{IN88US=> M12xdHNCVkeHUh?=
SW872 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXSRmdKSzVyPUGuPFE{QTVizszN NW\XZZJyW0GQR1XS
TK10 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwOEOxNFgh|ryP M4DPZXNCVkeHUh?=
LB831-BLC MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTWTWM2OD1zLkizOVY{KM7:TR?= M3TucHNCVkeHUh?=
TE-9 NV7JU4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQTWlEPTB;MT64OFQzOiEQvF2= M3rk[nNCVkeHUh?=
MLMA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfZdGVKSzVyPUGuPFgzOzRizszN MmjRV2FPT0WU
D-542MG NFuzfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XzR2lEPTB;MT64PVM4OyEQvF2= Ml2zV2FPT0WU
EW-16 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XRTWlEPTB;MT65NlczKM7:TR?= NHLOTZBUSU6JRWK=
LOXIMVI MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwOUOyPEDPxE1? MlTSV2FPT0WU
GB-1 M4LMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHYcGNNUUN3ME2xMlk{QDZ4IN88US=> Mk\BV2FPT0WU
IST-SL2 NYL1dppuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIexRY9KSzVyPUKuNFAzPjJizszN NFrvPVlUSU6JRWK=
LAN-6 NGrROZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\3eHdOUUN3ME2yMlAyQTZ4IN88US=> MWjTRW5ITVJ?
NCI-H510A M4rXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP4fXFKSzVyPUKuNFQ2ODJizszN MWPTRW5ITVJ?
NCI-H1092 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XwbmlEPTB;Mj6wOVEzPCEQvF2= NV35e4dOW0GQR1XS
HT NXvSS5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\KTWM2OD1{LkGwOFU1KM7:TR?= MWTTRW5ITVJ?
RL95-2 M4S0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwMUG0PFIh|ryP M1f0VXNCVkeHUh?=
NCI-H1355 M3jWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vjTWlEPTB;Mj6xNVc6OiEQvF2= Ml\XV2FPT0WU
NCI-H720 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;2PIdQUUN3ME2yMlE3QDd|IN88US=> M2L1eXNCVkeHUh?=
NCI-H1522 NFPLW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDo[5FOUUN3ME2yMlIyPzJ|IN88US=> M1WwO3NCVkeHUh?=
LB373-MEL-D M2\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX74SYdkUUN3ME2yMlI3QTB{IN88US=> MnmxV2FPT0WU
DG-75 M2PaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwMkexOFgh|ryP M{DCXXNCVkeHUh?=
ML-2 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33XNmlEPTB;Mj6zNlg2PSEQvF2= NXK3NINVW0GQR1XS
SF126 NHnnNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CyO2lEPTB;Mj6zN|A6PCEQvF2= MoDOV2FPT0WU
MPP-89 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PaOWlEPTB;Mj6zN|E1PSEQvF2= M2nsbHNCVkeHUh?=
NCI-H345 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwM{OyO|ch|ryP NIfjPZpUSU6JRWK=
LS-123 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nhfmlEPTB;Mj6zOFk{PiEQvF2= MoXBV2FPT0WU
NB10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofNTWM2OD1{LkSxNFkzKM7:TR?= NYjndmZzW0GQR1XS
CGTH-W-1 NHewdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnC[m5KSzVyPUKuOFIzPjdizszN NHm0c3NUSU6JRWK=
CP66-MEL MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonUTWM2OD1{LkS3O|ch|ryP MX3TRW5ITVJ?
L-428 NGC2dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HNcGlEPTB;Mj60PFUzOSEQvF2= M2T2NnNCVkeHUh?=
DMS-79 M2iybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwNUSxNFMh|ryP M1nUPHNCVkeHUh?=
NCI-H1882 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjUZZGUUN3ME2yMlY4PTZ{IN88US=> NGfXV4dUSU6JRWK=
KGN Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjmSJlFUUN3ME2yMlc3QDd4IN88US=> MYrTRW5ITVJ?
EW-1 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rifGlEPTB;Mj63O|A5OyEQvF2= MmLWV2FPT0WU
U-266 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnraTWM2OD1{Lki0PFI{KM7:TR?= NVW3PYZSW0GQR1XS
COLO-320-HSR M4\jbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwOEW2OFEh|ryP NEGwTWlUSU6JRWK=
KMOE-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUdGlEPTB;Mj64O|cyOSEQvF2= NEHxW4FUSU6JRWK=
BB49-HNC MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ITWM2OD1{LkmyOFgh|ryP MlHrV2FPT0WU
GI-1 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP5NZJKSzVyPUKuPVI6PTdizszN Mn7jV2FPT0WU
NCI-H1304 M3nr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzD[ZB[UUN3ME2zMlAxPTFzIN88US=> NYT0VpE3W0GQR1XS
NCI-H2227 NGDMZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjMRXdKSzVyPUOuNFIxPzlizszN MWTTRW5ITVJ?
U-87-MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnuTWM2OD1|LkCzOVE{KM7:TR?= NFrTdWFUSU6JRWK=
NCI-H747 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\pPZpKSzVyPUOuNFUzODZizszN NV\FOXVrW0GQR1XS
CTB-1 M2TMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrDO|hKSzVyPUOuNFU{PzZizszN NXOzXnplW0GQR1XS
RPMI-8226 M3TJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjyVZZKSzVyPUOuNVQ{PzhizszN NIfQSZlUSU6JRWK=
NCI-H2141 NGnJVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vndmlEPTB;Mz6xOlU3PiEQvF2= NEnBOHBUSU6JRWK=
IST-MES1 NGnuOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX4TWM2OD1|LkG4Nlc6KM7:TR?= M3n1WXNCVkeHUh?=
TE-5 NH[xTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e0W2lEPTB;Mz6yNVM1OiEQvF2= NFO1[pRUSU6JRWK=
UACC-257 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxTWM2OD1|LkSzOlU6KM7:TR?= MnS4V2FPT0WU
SK-N-FI MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfucWxkUUN3ME2zMlQ2OjJ5IN88US=> M4f2OnNCVkeHUh?=
MFH-ino MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLQcpVKSzVyPUOuOFY2QDlizszN MXzTRW5ITVJ?
SF268 NY\afIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC0TWM2OD1|LkS4NVc1KM7:TR?= M4jS[nNCVkeHUh?=
TE-12 M37wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNwNUG2PVkh|ryP MWTTRW5ITVJ?
NB6 NILubJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNUW1OlMh|ryP NHLoOFVUSU6JRWK=
DJM-1 NWexc3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnmbFExUUN3ME2zMlU6QDl7IN88US=> M{XyR3NCVkeHUh?=
MZ1-PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwNkG2NlQh|ryP NXzrNWtmW0GQR1XS
OCI-AML2 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJR2lEPTB;Mz62NlY4OSEQvF2= Mo[0V2FPT0WU
NCI-H1155 M4fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rzeGlEPTB;Mz63NFk1PyEQvF2= NVPQSYFlW0GQR1XS
RKO MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHuTWM2OD1|Lke3NVg6KM7:TR?= Mn:3V2FPT0WU
ECC4 NWS1ZlBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{flRmlEPTB;Mz65O|E6PSEQvF2= MmfGV2FPT0WU
BB65-RCC MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLVTWM2OD1|Lkm3OVQ4KM7:TR?= NH[2VlRUSU6JRWK=
EB-3 NXXnNmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwOUm2N|Mh|ryP NH7xepJUSU6JRWK=
SHP-77 NYXmc4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW4S49wUUN3ME20MlAxPTJ2IN88US=> Mli5V2FPT0WU
NCI-H2196 NFfHbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPxeHlKSzVyPUSuNFU3OjVizszN NUXLUGJEW0GQR1XS
GI-ME-N NGexNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF62OI5KSzVyPUSuNFY{QTlizszN MoDIV2FPT0WU
MN-60 M4HBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDTWM2OD12LkGwPFch|ryP NGDJbmlUSU6JRWK=
NCI-H1694 NHW2N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvflFKSzVyPUSuNVM1ODVizszN MUXTRW5ITVJ?
LU-65 M1L4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwMUWzN|Ih|ryP NYjIbZNzW0GQR1XS
NCI-H1436 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnEUpRKSzVyPUSuNVg{OzNizszN M2G3TnNCVkeHUh?=
KINGS-1 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqxTWM2OD12LkOxOFMzKM7:TR?= Mlm2V2FPT0WU
GT3TKB NGS3eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzITWM2OD12LkOzNlY5KM7:TR?= NGn4e3BUSU6JRWK=
Becker NVXWOmx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2fmFtUUN3ME20MlM4OzF{IN88US=> MVXTRW5ITVJ?
HCC1187 NX72TVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHEN|h5UUN3ME20Mlg6PjV5IN88US=> M{i1PXNCVkeHUh?=
D-502MG MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK0O5pKSzVyPUWuNFA1OTZizszN MkDLV2FPT0WU
VA-ES-BJ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TReWlEPTB;NT6xN|c4QCEQvF2= M4TUcXNCVkeHUh?=
NB7 NF;ydFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LufmlEPTB;NT6xOFEyOiEQvF2= M2r2bXNCVkeHUh?=
SW962 M1OyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTVwM{i4NVQh|ryP M2TDRnNCVkeHUh?=
no-11 NVjuOWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fNbmlEPTB;NT63OlM1OyEQvF2= M3;QdXNCVkeHUh?=
KNS-81-FD MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Wd2hnUUN3ME21MlkxPjl2IN88US=> MkPtV2FPT0WU
COLO-684 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S4UGlEPTB;NT65PVQ6PCEQvF2= NWfRVFRMW0GQR1XS
D-263MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG1TWM2OD14LkC4PFk2KM7:TR?= NX2wdml5W0GQR1XS
EW-24 M1jCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPETWM2OD14LkK4OVEh|ryP M3jCWnNCVkeHUh?=
TE-10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCXWlEPTB;Nj60NlYzOyEQvF2= MkTiV2FPT0WU
EKVX NUPzV2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v0d2lEPTB;Nj60OlMzOSEQvF2= MoTuV2FPT0WU
NCI-H1648 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZwNke1OVch|ryP NYTRcHg2W0GQR1XS
LB771-HNC M{PacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[2bJpKSzVyPU[uPVI{ODFizszN MoTXV2FPT0WU
SK-MEL-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrkTWM2OD16LkGzNVY3KM7:TR?= NYjqbVdHW0GQR1XS
COLO-668 NUi2XlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD16LkK3O|g3KM7:TR?= MnXFV2FPT0WU
EW-12 NGTFWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRThwNEC4NFMh|ryP MonzV2FPT0WU
A253 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[3NJNoUUN3ME24Mlg1PjZzIN88US=> M3f3WHNCVkeHUh?=
NCI-H2126 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jaeGlEPTB;OD64PVMyQSEQvF2= MmnRV2FPT0WU
Calu-6 NIn6[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PDe2lEPTB;OD65PVA1OiEQvF2= M1WxeHNCVkeHUh?=
NCI-H23 M2XqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnWTWM2OD17LkG3O|Q3KM7:TR?= M3PLU3NCVkeHUh?=
WSU-NHL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SyV2lEPTB;OT63O|Q4QCEQvF2= MkfQV2FPT0WU
MMAC-SF MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvUTWM2OD17Lkm3PVA1KM7:TR?= NV;zfHJbW0GQR1XS
SK-LMS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDSWHY5UUN3ME2xNE4zQDN2IN88US=> MoH0V2FPT0WU
GCIY MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzid5FUUUN3ME2xNE42QTJ2IN88US=> NYrnWZN5W0GQR1XS
TE-15 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFzLk[wNFQh|ryP NXOwcIVmW0GQR1XS
EoL-1-cell M3rBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLke2PFIh|ryP M4TJWXNCVkeHUh?=
NCI-H2081 NXH6WINsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHDTWM2OD1zMT63O|g3KM7:TR?= Mkf2V2FPT0WU
EW-3 M2\pTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF{LkK0OlMh|ryP MnfyV2FPT0WU
CAS-1 NHnTe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[wblg3UUN3ME2xNk4{PjNzIN88US=> NH\Be5BUSU6JRWK=
C2BBe1 NF\TboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW2Z2g3UUN3ME2xNk43OTNzIN88US=> NVnlT446W0GQR1XS
D-247MG MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHWTWM2OD1zMj63PVUzKM7:TR?= NF:zToxUSU6JRWK=
NCI-SNU-5 NV7iN|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPHTpBGUUN3ME2xNk45ODF|IN88US=> MWrTRW5ITVJ?
LS-1034 NF\FeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF2LkO5O|Uh|ryP NUGydlI6W0GQR1XS
EW-18 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK3TWM2OD1zND60OFgh|ryP MnGyV2FPT0WU
Raji MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHWNm9LUUN3ME2xOE42ODR7IN88US=> Mn;hV2FPT0WU
D-283MED MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDMTWM2OD1zND62NlcyKM7:TR?= NX\PfYFPW0GQR1XS
MZ2-MEL NGr6S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjnTWM2OD1zND65Olk3KM7:TR?= M13tfXNCVkeHUh?=
NCI-SNU-16 M120VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrycoJKSzVyPUG1MlQ3OzNizszN NGW3SIRUSU6JRWK=
P30-OHK MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLRTWM2OD1zNz63PFMyKM7:TR?= NX3Dd5Z7W0GQR1XS
RXF393 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfNNmFXUUN3ME2xPU4xOTh4IN88US=> M3nYT3NCVkeHUh?=
NCI-H1395 NELKPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHlSVBKSzVyPUKwMlY4ODNizszN MYHTRW5ITVJ?
U-698-M M{HBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPURotsUUN3ME2yNE44ODd3IN88US=> MmnWV2FPT0WU
NCI-SNU-1 M17aRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\4cI41UUN3ME2yNE44OjJ|IN88US=> MV3TRW5ITVJ?
SW684 NFzJ[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjN[ldKSzVyPUKxMlE4OTZizszN M1fyR3NCVkeHUh?=
NCI-H716 M4m4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTiTWM2OD1{MT6zNVU1KM7:TR?= NXXJTZF6W0GQR1XS
JVM-2 NFG5N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfTRlhIUUN3ME2yNU41OTN|IN88US=> NX;nR3hNW0GQR1XS
NCI-H1581 NWrkc4RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ{LkSxOFgh|ryP M1\yN3NCVkeHUh?=
CA46 NUXFfWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfnS|hKSzVyPUOxMlY6OzZizszN MnLCV2FPT0WU
SNB75 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHMTWM2OD1|Mz62OVA{KM7:TR?= MVnTRW5ITVJ?
KNS-42 NEX3dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DQPGlEPTB;M{WuPVYzPCEQvF2= NEnDVW5USU6JRWK=
TUR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzoeG9KSzVyPUO2MlA2OjFizszN MXTTRW5ITVJ?
REH M1:4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN5LkiyNVEh|ryP MYrTRW5ITVJ?
EW-22 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jNb2lEPTB;NEKuNlg5PSEQvF2= MYnTRW5ITVJ?
NCI-H446 NYnUdFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP4bXB1UUN3ME20Nk44QDV|IN88US=> NXK3SmFpW0GQR1XS
ES3 M1\abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTR|LkGzN|kh|ryP MmG3V2FPT0WU
EW-11 NX\XWotsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR2LkiyNVgh|ryP MXnTRW5ITVJ?
RH-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm4e5dPUUN3ME20O{42QDF{IN88US=> NIHuN5JUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

- Collapse

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

- Collapse
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID